Clarus Therapeutics Holdings, Inc. (CRXTQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clarus Therapeutics Holdings, Inc. (CRXTQ) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 68/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 18 mar 2026Clarus Therapeutics Holdings, Inc. (CRXTQ) Resumen de Asistencia Médica y Tuberías
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company specializing in oral testosterone replacement therapy, primarily JATENZO, targeting hypogonadal men. Facing financial challenges, the company filed for Chapter 11 reorganization and now operates on the OTC market, navigating a competitive landscape of established pharmaceutical companies.
Tesis de Inversión
Clarus Therapeutics Holdings, Inc. faces significant challenges following its Chapter 11 filing in September 2022. The company's primary asset, JATENZO, targets a specific market segment within testosterone replacement therapy. The company's gross margin stands at 80.5%. However, the company's profit margin is -404.9%. Trading on the OTC market introduces liquidity and regulatory risks. Potential investors should carefully consider the implications of the bankruptcy proceedings and the inherent risks associated with OTC-listed companies before making any investment decisions. The company's future hinges on successful restructuring and potential strategic partnerships.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 80.5% indicates strong potential profitability on sales before operating expenses.
- Filed for Chapter 11 reorganization on September 5, 2022, impacting financial stability and future operations.
- Offers JATENZO, an oral testosterone replacement therapy, targeting the hypogonadal men market.
- Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
- Profit Margin of -404.9% signals significant financial losses and operational inefficiencies.
Competidores y Pares
Fortalezas
- Proprietary oral formulation of testosterone (JATENZO).
- Licensing agreements for potential new therapies.
- Established presence in the testosterone replacement market.
- Gross margin of 80.5%.
Debilidades
- Chapter 11 bankruptcy filing.
- Negative profit margin (-404.9%).
- Limited product portfolio concentrated on JATENZO.
- Trading on the OTC market with associated risks.
Catalizadores
- Ongoing: Restructuring efforts under Chapter 11 bankruptcy proceedings could lead to improved financial stability and operational efficiency.
- Upcoming: Potential FDA approvals for new therapies developed through licensing agreements with HavaH Therapeutics and McGill University.
- Ongoing: Strategic partnerships or acquisitions to expand the product portfolio and market reach.
Riesgos
- Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.
- Potential: Competition from established pharmaceutical companies and generic drug manufacturers.
- Potential: Regulatory challenges and potential changes in guidelines for testosterone replacement therapy.
- Ongoing: Limited financial disclosure and transparency due to OTC listing.
- Potential: Low trading volume and liquidity on the OTC market.
Oportunidades de crecimiento
- Expansion of JATENZO Market Share: Clarus has the opportunity to increase the market share of JATENZO within the oral testosterone replacement therapy segment. This can be achieved through targeted marketing campaigns, improved patient education, and strategic partnerships with healthcare providers. The global testosterone replacement therapy market is projected to reach $2.1 billion by 2027, providing a substantial market for JATENZO to penetrate further. Timeline: Ongoing.
- Development of New Androgen Therapies: The licensing agreement with HavaH Therapeutics presents an opportunity to develop novel androgen therapies for inflammatory breast disease and certain forms of breast cancer. Successful development and commercialization of these therapies could diversify Clarus's product portfolio and tap into new therapeutic areas. The market for breast cancer therapies is estimated to reach $30 billion by 2028. Timeline: 3-5 years.
- Commercialization of CoQ10 Deficiency Treatment: The license agreement with McGill University to develop and commercialize technology for treating CoQ10 deficiencies offers another avenue for growth. CoQ10 deficiencies are associated with various neurological and muscular disorders, representing a significant unmet medical need. The market for CoQ10 supplements and treatments is growing, driven by increasing awareness of its health benefits. Timeline: 3-5 years.
- Strategic Partnerships and Acquisitions: Clarus could pursue strategic partnerships or acquisitions to expand its product portfolio, access new markets, or enhance its research and development capabilities. Collaborations with other pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of new therapies. The pharmaceutical industry is characterized by frequent mergers and acquisitions, providing opportunities for Clarus to participate in consolidation. Timeline: Ongoing.
- Restructuring and Financial Turnaround: Successful restructuring under Chapter 11 could provide Clarus with a fresh start and the opportunity to streamline its operations, reduce its debt burden, and improve its financial performance. A successful turnaround could restore investor confidence and unlock the company's long-term growth potential. The timeline for restructuring is dependent on the bankruptcy court proceedings and the company's ability to negotiate with creditors. Timeline: 1-2 years.
Oportunidades
- Expansion of JATENZO market share.
- Development and commercialization of new androgen therapies.
- Commercialization of CoQ10 deficiency treatment.
- Strategic partnerships and acquisitions.
Amenazas
- Competition from established pharmaceutical companies.
- Regulatory challenges and potential changes in guidelines.
- Generic competition for JATENZO.
- Economic downturn impacting healthcare spending.
Ventajas competitivas
- Proprietary oral formulation of testosterone undecanoate (JATENZO).
- Licensing agreements for novel androgen therapies and CoQ10 deficiency treatments.
- Established presence in the testosterone replacement therapy market.
- Intellectual property protection for JATENZO and other pipeline products.
Acerca de CRXTQ
Founded in 2003 and based in Northbrook, Illinois, Clarus Therapeutics Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing oral testosterone replacement therapies. Its primary product, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed to treat hypogonadal men. This therapy offers an alternative to traditional testosterone replacement methods, such as injections or topical gels. In addition to JATENZO, Clarus has licensing agreements with HavaH Therapeutics to develop androgen therapies for inflammatory breast disease and certain forms of breast cancer. They also have a license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. However, on September 5, 2022, Clarus Therapeutics Holdings, Inc. and its affiliate filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware, impacting its operational and financial stability. The company now trades on the OTC market.
Qué hacen
- Develop and commercialize oral testosterone replacement therapy.
- Offer JATENZO, a soft gel oral formulation of testosterone undecanoate.
- Target hypogonadal men with testosterone deficiency.
- Hold licensing agreements for androgen therapies targeting inflammatory breast disease and breast cancer.
- Collaborate with McGill University to develop treatments for CoQ10 deficiencies.
- Operate in the pharmaceutical industry, subject to regulatory approvals and market competition.
Modelo de Negocio
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market JATENZO for testosterone replacement therapy.
- Generate revenue through sales of JATENZO.
- License technology and collaborate with other companies for new product development.
Contexto de la Industria
Clarus Therapeutics Holdings, Inc. operates within the drug manufacturing industry, focusing on therapies for hormone replacement. The market for testosterone replacement therapy is driven by an aging population and increasing awareness of hypogonadism. However, the industry is highly competitive, with established pharmaceutical companies and generic drug manufacturers vying for market share. Clarus faces competition from companies offering alternative testosterone delivery methods, such as injections, topical gels, and patches. The company's Chapter 11 filing adds another layer of complexity in a sector characterized by stringent regulatory requirements and high research and development costs.
Clientes Clave
- Hypogonadal men diagnosed with testosterone deficiency.
- Healthcare providers who prescribe testosterone replacement therapy.
- Pharmacies that dispense JATENZO.
- Patients seeking oral alternatives to traditional testosterone treatments.
Finanzas
Gráfico e información
Precio de la acción de Clarus Therapeutics Holdings, Inc. (CRXTQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CRXTQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CRXTQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CRXTQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CRXTQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Robert E. Dudley
CEO
Robert E. Dudley serves as the CEO of Clarus Therapeutics Holdings, Inc. His leadership experience includes managing teams and overseeing the development and commercialization of pharmaceutical products. His expertise lies in the pharmaceutical industry, with a focus on hormone replacement therapies and related therapeutic areas. He is responsible for guiding the company through its current financial challenges and strategic restructuring efforts.
Historial: Under Robert E. Dudley's leadership, Clarus Therapeutics Holdings, Inc. has focused on expanding the market reach of JATENZO and pursuing licensing agreements for new therapies. However, the company filed for Chapter 11 reorganization during his tenure, presenting a significant challenge to his leadership and the company's future prospects. He is currently focused on navigating the restructuring process and seeking opportunities for financial recovery.
Información del mercado OTC de CRXTQ
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often belong to companies that are distressed, undergoing bankruptcy, or have limited financial disclosure. Companies in this tier may not meet minimum financial standards and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other securities carries a higher degree of risk due to the lack of transparency and liquidity.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for significant price volatility.
- Risk of delisting or suspension of trading.
- Uncertainty related to Chapter 11 bankruptcy proceedings.
- Verify the company's current financial status and bankruptcy proceedings.
- Review any available financial reports and disclosures.
- Assess the trading volume and bid-ask spread for CRXTQ.
- Research the company's management team and their experience.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before making any investment decisions.
- Established presence in the testosterone replacement therapy market prior to bankruptcy.
- Proprietary oral formulation of testosterone (JATENZO).
- Licensing agreements for potential new therapies.
- Continued operations during Chapter 11 reorganization.
CRXTQ Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar CRXTQ?
Clarus Therapeutics Holdings, Inc. (CRXTQ) actualmente tiene una puntuación IA de 68/100, indicando puntuación moderada. Fortaleza clave: Proprietary oral formulation of testosterone (JATENZO).. Riesgo principal a monitorear: Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CRXTQ?
CRXTQ actualmente puntúa 68/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CRXTQ?
Los precios de CRXTQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CRXTQ?
La cobertura de analistas para CRXTQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CRXTQ?
Las categorías de riesgo para CRXTQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CRXTQ?
La relación P/E para CRXTQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CRXTQ sobrevalorada o infravalorada?
Determinar si Clarus Therapeutics Holdings, Inc. (CRXTQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CRXTQ?
Clarus Therapeutics Holdings, Inc. (CRXTQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be limited due to the company's OTC listing and Chapter 11 status.
- Financial data may not be fully up-to-date due to the bankruptcy proceedings.